Breast Cancer Research and Treatment

Article	Citations
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival	121
Nuclear magnetic resonance-determined lipoprotein profile and risk of breast cancer: a Mendelian randomization study	78
Intraoperative assessment of axillary sentinel lymph nodes by telepathology	75
Prognostic and predictive impact of NOTCH1 in early breast cancer	72
Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia	62
Surveillance mammography after treatment for male breast cancer	62
Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis	61
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer	57
Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study	49
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients	48
Long-term dietary intervention influence on physical activity in the Women’s Health Initiative Dietary Modification randomized trial	44
Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy	43
Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe	40
Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis	39
Area deprivation index and breast cancer outcomes among patients in Western New York	39
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study	38
Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study	36
The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study	33
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)	33
Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials	33
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis	33
Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience	31
Endocrine adherence in male versus female breast cancer: a seer-medicare review	30
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy	29
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer	29

Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in high-risk Pakistani breast cancer patients	28
Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase	28
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer	27
Integrating SENOMAC and AMAROS: a call for de-escalation	27
Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy	26
Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990–2019: an examination using estimates from the global burde	26
Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer	26
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers	26
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial	25
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies	25
Exploring the intersectionality of race/ethnicity with rurality on breast cancer outcomes: SEER analysis, 2000–2016	24
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective study	24
SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast	24
Identifying gene expression predictive of response to neoadjuvant endocrine therapy in early breast cancer	23
Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis	23
Outcomes of Stage I and II Breast Cancer with Nodal Micrometastases Treated with Mastectomy without Axillary Therapy	23
Correction to: Pathogenic variants among females with breast cancer and a non‑breast cancer reveal opportunities for cancer interception	22
Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival—a propensity score cohort study	22
Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study	22
Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021	22
Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study	22
Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings	21
Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a media	21
Multigene panel testing might explain the increased risk of secondary malignancies after radiotherapy in Japanese breast cancer patients	21
A retrospective study evaluating the impact of scattering radiation from imaging procedures on oocyte quality during ovarian stimulation for fertility preservation in young breast cancer patients	21
Gaps in completion and timeliness of breast surgery and adjuvant therapy: a retrospective cohort of Haitian patients with nonmetastatic breast cancer	21
Chemotherapy for ipsilateral breast tumor recurrence: a propensity score-matching study	21
Induction of SGK1 via glucocorticoid-influenced clinical outcome of triple-negative breast cancer patients	20
A novel long non-coding RNA regulates the integrin, ITGA2 in breast cancer	20
Prediction of nipple involvement in breast cancer after neoadjuvant chemotherapy: Should we rely on breast MRI to preserve the nipple?	20
Germline pathogenic variants associated with triple-negative breast cancer in US Hispanic and Guatemalan women using hospital and community-based recruitment strategies	20
Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry	20
Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy	19
Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study	19
Rates of price disclosure associated with the surgical treatment of early-stage breast cancer one year after implementation of federal regulations	19
Letter to the Editor in response to paper “BRCA1 promoter methylation in triple-negative breast cancer……” by K Daster et al	19
Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics	19
Enhancing surgical precision: active marker localization at the time of biopsy in breast cancer management	19
Correction: Taxane/anthracycline combinations reduced incidence of breast cancer recurrence in young women across molecular subtypes: a real-world evidence of Taiwan from 2011 to 2019	19
Clinical trials of immunotherapy in triple-negative breast cancer	18
Unveiling the role of PANoptosis-related genes in breast cancer: an integrated study by multi-omics analysis and machine learning algorithms	18
Hormone-associated dietary patterns and premenopausal breast cancer risk	18
Ocular adverse events of perioperative adjuvant docetaxel vs paclitaxel for breast cancer: propensity-score overlap-weighted analysis	18
PD-L1 22C3 CPS in paired primary breast cancer and lung metastasis	17
Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population	17
Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent ki	17
Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression	17
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk	17
Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene	17
Relationship between tamoxifen and cataracts: a nationwide cohort study of women in South Korea	16

Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer	16
Double-negative T cells with a distinct transcriptomic profile are abundant in the peripheral blood of patients with breast cancer	16
Racial and ethnic disparities in the refusal of surgical treatment in women 40 years and older with breast cancer in the USA between 2010 and 2017	16
Dual targeting of HSP90 and BCL-2 in breast cancer cells using inhibitors BIIB021 and ABT-263	16
Omission of multimodal therapy in older adults with high-risk breast cancer	16
Early postoperative psychological distress as a mediator of subsequent persistent postsurgical pain outcomes among younger breast cancer patients	16
A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets for breast cancer	16
Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma	16
Social inequalities in the use of physiotherapy in women diagnosed with breast cancer in Barcelona: DAMA cohort	16
Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese organization of hereditary breast and ovarian cancer regist	16
Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy	16
Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial	15
Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapy—results of the multicenter UMBRELLA breast cancer cohort	15
Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?	15
APX2009 sensitizes hypoxic breast cancer cells to doxorubicin by increasing its accumulation and caspase-3/7-mediated apoptosis	15
Digital mammography and digital breast tomosynthesis for detecting invasive lobular and ductal carcinoma	15
Association between body mass index and outcomes after autologous breast reconstruction: a nationwide inpatient database study in Japan	15
Multi-omics portrait of ductal carcinoma in situ in young women	15
Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer: a nationwide study	15
Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status	15
Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients	15
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer	15
Strict definition of a small tumor in breast cancer should be revisited	15
Preferences of patients with high-risk HR + /HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany	15
A novel role of IGFBP5 in the migration, invasion and spheroids formation induced by IGF-I and insulin in MCF-7 breast cancer cells	15
Clinical and sociodemographic determinants of older breast cancer survivors’ reports of receiving advice about exercise	15
Tumor infiltrating lymphocytes and change in tumor load on MRI to assess response and prognosis after neoadjuvant chemotherapy in breast cancer	15
HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles	15
Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer	14
A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group’s (DBCG) NAME-trial	14
Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer	14
Insulin resistance and the development of breast cancer in premenopausal women: the Kangbuk Samsung Health Study	14
Superficial and functional imaging of the tricipital lymphatic pathway: a modern reintroduction	14
Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice	14
Oncologic and cosmetic outcomes of oncoplastic breast-conserving surgery after neoadjuvant systemic therapy: systematic review and meta-analysis	14
Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study	14
Male breast cancer: a multicenter study to provide a guide for proper management	14
Influence of tumour grade on disease survival in male breast cancer patients: a systematic review	14
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study	14
Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer	14
Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue	14
Prognostic significance of abdominal obesity and its post-diagnosis change in a Chinese breast cancer cohort	14
Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world	14
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)	14
Cholesterol and breast cancer risk: a cohort study using health insurance claims and health checkup databases	14
Influence of rurality on lymph node assessment among women diagnosed with ductal carcinoma in situ and treated with mastectomy, SEER 2000–2015	13
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer	13
Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis	13
Endocrine therapy initiation among women with stage I–III invasive, hormone receptor-positive breast cancer from 2001–2016	13
Re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)	13
Penetrance of male breast cancer susceptibility genes: a systematic review	13
Aging-accumulated methylmalonic acid serum levels at breast cancer diagnosis are not associated with distant metastases	13
Intratumoral PDGFB gene predominantly expressed in endothelial cells is associated with angiogenesis and lymphangiogenesis, but not with metastasis in breast cancer	13
Changes in the survival of patients with breast cancer: Poland, 2000–2019	13
Letter to the editor regarding “Association between gout and subsequent breast cancer: a retrospective cohort study including 67,598 primary care patients in Germany”	13
Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis	13
A mixed method study of medical oncologists’ perceived barriers and motivators to addressing long-term effects in breast cancer survivors	13
Quantifying radiation in the axillary bed at the site of lymphedema surgical prevention	13
Correction: Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics	13
Burden and trajectory of social needs after breast cancer diagnosis at a safety-net hospital	13
BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors	13
Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials	13
BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer	13
Correlation analysis between shear-wave elastography and pathological profiles in breast cancer	13
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium	13
Socioeconomic status impacts tumor biology, treatment, and outcomes in over 200,000 patients with invasive lobular carcinoma of the breast: an analysis of the National Cancer Database	12
Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study	12
PGM5P3-AS1 regulates MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of triple-negative breast cancer	12
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy	12
The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancer	12
The importance of SOCS1 − 1478 CA/del polymorphism and expression in breast cancer: a case–control study in the north of Iran	12
Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer	12
Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer	12
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial	12
A comparative analysis of recurrence risk predictions in ER+/HER2− early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast	12
Secretory breast carcinoma: a multicenter clinicopathologic study of 80 cases with emphasis on prognostic analysis and chemotherapy benefit	12
Multi-level factors drive use of sentinel lymph node biopsy in older women with early-stage breast cancer	12
Organoid models derived from patients with malignant phyllodes tumor of the breast	12
Reply to: “Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)”	12
Factors associated with breast cancer detection method in California women: an analysis of California Health Interview Survey data	12

Relations between recurrence risk perceptions and fear of cancer recurrence in breast cancer survivors	12
Association of body composition and surgical outcomes in patients with early-stage breast cancer	12
The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey	12
Single-institution outcomes after excision of benign phyllodes tumors: low recurrence risk even with positive margins	12
Optimizing surgical strategy in locally advanced breast cancer: a comparative analysis between preoperative MRI and postoperative pathology after neoadjuvant chemotherapy	12
Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center	12
An overview of genetic services delivery for hereditary breast cancer	12
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative br	12
High neuroticism is associated with common late adverse effects in a nationwide sample of long-term breast cancer survivors	12
Diagnostic performance of MRI-guided vacuum-assisted breast biopsy (VABB): an essential but still underused technique	12
Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age	12
Reciprocal regulation of forkhead box C1 and L1 cell adhesion molecule contributes to triple-negative breast cancer progression	12
Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast)	12
Effects of exercise in breast cancer patients: implications of the trials within cohorts (TwiCs) design in the UMBRELLA Fit trial	12
Neighborhood characteristics and breast tumor methylation: using epigenomics to explore cancer outcome disparities	12
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer	12
Breast magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy and immunotherapy in early triple-negative breast cancer patients: prediction of pathological response and	12
Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study	12
Diagnostic performance of screening mammography according to menstrual cycle among Asian women	11
BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses	11
Circadian rhythm disrupting behaviours and cancer outcomes in breast cancer survivors: a systematic review	11
Correction: The novel TP53 3′-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection	11
Clinico–pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis	11
Severe hyponatremia with abemaciclib use in the absence of pre-existing renal disease	11
Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer	11
Effect of pretreatment lab abnormalities on the time-to-treatment discontinuation and overall survival of metastatic breast cancer patients receiving CDK 4/6i, PI3Ki, and/or mTORi	11
Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis	11
Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients	11
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41	11
Tumor-associated mononuclear cells in the tumor bed of triple-negative breast cancer associate with clinical outcomes in the post-neoadjuvant chemotherapy setting	11
Relationship between oily fish intake and breast cancer based on estrogen receptor status: a Mendelian randomization study	11
The differences between pure and mixed invasive micropapillary breast cancer: the epithelial–mesenchymal transition molecules and prognosis	11
Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review	11
Lumpectomy surgery for large ductal carcinoma in situ	11
Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis	11
Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome	11
Radiation recall dermatitis induced by abemaciclib with successful rechallenge: a case series and literature review	11
Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer	11
Indocyanine green angiography guidance for vascular preservation in skin and nipple sparing mastectomy	11
A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1–CDK4 interaction	11
Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey	11
Spectrum of germline pathogenic variants in Brazilian hereditary breast/ovarian cancer cases	11
Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark	11
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study	11
Identifying research priorities for improving information and support for patients undergoing breast cancer surgery: a UK patient-centred priority setting project	11
The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study	11
Is axillary web syndrome a risk factor for breast cancer-related lymphedema of the upper extremity? A systematic review and meta-analysis	11
Estimating the incidence of breast cancer recurrence using administrative data	11
HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series	11
Suppression of breast cancer metastatic behavior by microRNAs targeting EMT transcription factors. A relevant participation of miR-196a-5p and miR-22-3p in ZEB1 expression	11
Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy	11
Perceptions of breast cancer risk after breast density notification in a population-based screening program	11
Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study	11
Comparing quality of breast cancer care in the Netherlands and Norway by federated propensity score analytics	10
Safe perioperative tamoxifen use in autologous breast free flap reconstruction: systematic review and meta-analysis	10
Does a brief surgeon training in negotiation theory principles decrease rates of contralateral prophylactic mastectomy?	10
Is de-escalation of treatment by omission of radiotherapy associated with fear of cancer recurrence in women with early breast cancer? An exploratory study	10
Utilization and predictors of postmastectomy radiation receipt in an Oncology Center in Zimbabwe	10
Molecular Dynamics of Breast Cancer Subtypes: The Role of FAM83H-AS1 Long Non-coding RNA in Breast Cancer Metastasis	10
Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry	10
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, car	10
Impact of diabetes on surgery and radiotherapy for breast cancer	10
Limitations of locoregional and distant recurrence analysis after neoadjuvant chemotherapy	10
Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers	10
Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)	10
Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin	10
History of infertility and risk of breast cancer: a prospective cohort study	10
Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center	10
Molecular characterization of ESR1 variants in breast cancer	10
Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors	10
Risk of secondary malignancy after radiotherapy for breast cancer: long-term follow-up of Japanese patients with breast cancer	10
Association between body mass index and incidence of breast cancer in premenopausal women: a Japanese nationwide database study	10
Reply to Bourgeois P.	10
Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis	10
Long-term benefits of exercise interventions during chemotherapy in breast cancer: insights from the optitrain trial calling for longitudinal studies	10
Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ	10
USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells	10
Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study	10
Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy	9
Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer	9
Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer	9
Metastatic pure invasive lobular breast cancer or metastatic mixed invasive ductal and lobular breast cancer: are they different entities?	9
Genetic testing in women with early-onset breast cancer: a Traceback pilot study	9
Standardization of the tumor-stroma ratio scoring method for breast cancer research	9
Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer	9
Stalled at the intersection: insurance status and disparities in post-mastectomy breast reconstruction	9
Hypofractionated proton therapy in breast cancer: where are we? A critical review of the literature	9
Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system	9
Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor	9
Oncologic safety of axillary lymph node dissection with immediate lymphatic reconstruction	9
A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer	9
Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care	9
Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study	9
Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis	9
Letter to the BRCT editor	9